Literature DB >> 6311878

Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders.

S Martin, S C Baldock, A T Ghoneim, J A Child.   

Abstract

Neutrophil function studies have been carried out in a series of 44 patients with primary myelodysplastic syndromes (MDS). In vitro tests of phagocytosis and killing of Candida guilliermondii and Staphylococcus aureus identified 13 patients with abnormal neutrophil function at presentation and a further 10 who developed abnormalities during the course of their disease. The incidence of defective function in the five disease categories in this series was: refractory cytopenia (RC) 8/17; refractory cytopenia with sideroblastic change (RC + SC) 5/8; acquired idiopathic sideroblastic anaemia (AISA) 2/4; refractory anaemia with excess blasts (RAEB) 7/11; chronic myelomonocytic leukaemia (CMML) 1/4. Eleven of 23 patients with defective neutrophil function experienced severe infective complications; in only three of these patients were neutrophil counts less than 1 X 10(9)/l and susceptibility to infection was considered to reflect, at least partially, qualitative neutrophil abnormalities. There was no correlation between absolute neutrophil count and defective function. Abnormal overall neutrophil microbicidal activity was equally associated with impaired and normal phagocytosis. Some patients with intracellular killing defects had reduced myeloperoxidase (MPO) activities and one had reduced hexose monophosphate shunt (HMPS) activity. In two patients, whose neutrophils showed markedly impaired candidacidal activity, levamisole corrected function when added in vitro at 10(-7) M and also when administered in therapeutic dosage. It is suggested that deranged function, probably reflecting abnormalities in maturation of the granulocyte series, occurs across the myelodysplastic spectrum and that several microbicidal mechanisms may be defective.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311878      PMCID: PMC498487          DOI: 10.1136/jcp.36.10.1120

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Granulocyte function in chronic granulocytic leukaemia. I. Bactericidal and metabolic capabilities during phagocytosis in isolated granulocytes.

Authors:  H Odeberg; T Olofsson; I Olsson
Journal:  Br J Haematol       Date:  1975-03       Impact factor: 6.998

2.  Partial myeloperoxidase deficiency in a case of preleukaemia. I. Studies of fine structure and peroxidase synthesis of promyelocytes.

Authors:  J Breton-Gorius; D Houssay; B Dreyfus
Journal:  Br J Haematol       Date:  1975-07       Impact factor: 6.998

3.  A statistical approach to the polymorphonuclear leukocyte bactericidal assay.

Authors:  T A Hoffman; W E Bullock
Journal:  J Lab Clin Med       Date:  1973-01

4.  Defective mononuclear phagocyte function in patients with myelomonocytic leukemia and in some patients with lymphoma.

Authors:  M J Cline
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

5.  Refractory megaloblastic anemia with myeloperoxidase-deficient neutrophils.

Authors:  R I Lehrer; L S Goldberg; M A Apple; N P Rosenthal
Journal:  Ann Intern Med       Date:  1972-03       Impact factor: 25.391

6.  NADPH oxidase deficiency in X-linked chronic granulomatous disease.

Authors:  D C Hohn; R I Lehrer
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

7.  Partial myeloperoxidase deficiency in a case of preleukaemia. II. Defects of degranulation and abnormal bactericidal activity of blood neutrophils.

Authors:  J Breton-Gorius; D Houssay; J L Vilde; B Dreyfus
Journal:  Br J Haematol       Date:  1975-07       Impact factor: 6.998

8.  In vitro stimulation of neutrophil motility by levamisole: maintenance of cgmp levels in chemotactically stimulated levamisole-treated neutrophils.

Authors:  R Anderson; A Glover; H J Koornhof; A R Rabson
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

9.  Defective neutrophil function in chronic granulocytic leukaemia.

Authors:  H El-Maalem; J Fletcher
Journal:  Br J Haematol       Date:  1976-09       Impact factor: 6.998

10.  Neutrophil granulocyte function in the early diagnosis of acute myelomonocytic and myeloblastic leukaemia.

Authors:  C O Solberg; K Schreiner; K B Hellum; E Hamre
Journal:  Acta Med Scand       Date:  1975-03
View more
  14 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.

Authors:  R E Clark; T G Hoy; A Jacobs
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

3.  Pyogenic abscesses in the myelodysplastic syndrome.

Authors:  P J Williamson; D G Oscier; G J Mufti; T J Hamblin
Journal:  BMJ       Date:  1989-08-05

4.  Large-vessel thrombosis in intestinal Behçet's disease complicated with myelodysplastic syndrome and trisomy 8.

Authors:  Huang-Chi Chen; Ying-Ming Chiu
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

5.  Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.

Authors:  R E Clark; S A Smith; A Jacobs
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

6.  Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome.

Authors:  Y Itoh; T Kuratsuji; S Aizawa; M Sai; K Ohyashiki; K Toyama
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

Review 7.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

8.  Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes.

Authors:  A Ohsaka; S Kitagawa; A Yuo; K Motoyoshi; S Furusawa; Y Miura; F Takaku; M Saito
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

9.  Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.

Authors:  G Seipelt; A Ganser; H Duranceyk; A Maurer; O G Ottmann; D Hoelzer
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

10.  Impairment of FOS mRNA stabilization following translation arrest in granulocytes from myelodysplastic syndrome patients.

Authors:  Xiaomin Feng; Yayoi Shikama; Tsutomu Shichishima; Hideyoshi Noji; Kazuhiko Ikeda; Kazuei Ogawa; Hideo Kimura; Yasuchika Takeishi; Junko Kimura
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.